Stay updated on SafetyEfficacy Patients 4+ Brain Metastases Melanoma Clinical Trial

Sign up to get notified when there's something new on the SafetyEfficacy Patients 4+ Brain Metastases Melanoma Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the SafetyEfficacy Patients 4+ Brain Metastases Melanoma Clinical Trial page

  1. Check
    4 days ago
    Change Detected
    Summary
    A temporary NIH announcement about terminology changes during an agency transition was removed from the page banner.
    Difference
    1%
    Check dated 2026-11-08T00:27:00.000Z thumbnail image
  2. Check
    11 days ago
    Change Detected
    Summary
    The ClinicalTrials.gov record for a phase II study of nivolumab and ipilimumab in melanoma patients with four or more symptomatic brain metastases is displayed, including study design, eligibility, outcomes, and locations. The record indicates the study was terminated due to lack of patients.
    Difference
    53%
    Check dated 2026-10-31T18:25:13.000Z thumbnail image
  3. Check
    18 days ago
    Change Detected
    Summary
    A site-wide banner announces NIH’s transition from using “Artificial Intelligence” to “Super Intelligence” terminology. It appears above the unavailable study record.
    Difference
    1%
    Check dated 2026-10-24T19:27:12.000Z thumbnail image
  4. Check
    25 days ago
    Change Detected
    Summary
    The site footer’s revision label changes from v3.7.1 to v3.7.2.
    Difference
    0.2%
    Check dated 2026-10-17T19:48:42.000Z thumbnail image
  5. Check
    32 days ago
    Change Detected
    Summary
    The site revision indicator in the footer changed from v3.7.0 to v3.7.1 on the access-denied page.
    Difference
    0.2%
    Check dated 2026-10-10T20:12:20.000Z thumbnail image
  6. Check
    53 days ago
    Change Detected
    Summary
    The page now displays a 403 Forbidden error indicating restricted access to the study record content. The additions include a 403 header and basic site chrome (such as Home and a revision notice), replacing the usual study details.
    Difference
    18%
    Check dated 2026-09-19T20:53:53.000Z thumbnail image

Stay in the know with updates to SafetyEfficacy Patients 4+ Brain Metastases Melanoma Clinical Trial

Enter your email address, and we'll notify you when there's something new on the SafetyEfficacy Patients 4+ Brain Metastases Melanoma Clinical Trial page.